The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines drug substance facility and an R&D pilot plant.

Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future ...

GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an expansion project ... The MAPS facility is expected to be completed ...

GSK Plc GSK has made an investment of over €250 million ($272 million) in a vaccine facility located in Belgium.. The company plans to construct a new section dedicated to freeze-drying vaccines ...

GlaxoSmithKline's Zebulon manufacturing site was temporarily shut down Tuesday August 11, 2015 after routine testing found Legionella bacteria isolated in a cooling tower.

MARIETTA, Pa. (WHTM) — A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster County manufacturing facility. During a press c… ...

Some 500 staff at a facility in Verona will be transferred from Glaxo to Aptuit.The London-based drug maker will also continue to. The Associated PressLONDON - PLC (NYSE: GSK) ...

The Big Pharma has decided to move its networking computing unit offsite to a TierPoint facility, a model it thinks will give it scalable and secure capacity that meets its uptime requirements.

The new manufacturing facility and the laboratory, which were developed with a €12m investment, were unveiled yesterday by Roger Connor, GSK’s global manufacturing supply president, and by Joe ...

Big Pharma firm GSK plans to invest up to $800 million to expand its manufacturing operations in Pennsylvania and create 200 new jobs.